Materiały źródłowe

• #1 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  In severe cases, thrombocytosis can cause dangerous clots in your blood vessels, increasing your risk of a stroke or heart attack. […] Your experience of thrombocytosis, including its seriousness and whether you need treatment, depends on its cause. […] High platelets aren’t life-threatening, but the complications that can result from the condition blood clots or severe bleeding can be. […] The most common causes of thrombocytosis are short-lived and don’t put you at risk of serious blood clots. The risk is greater with essential thrombocytosis. Still, your healthcare provider will monitor you closely, prescribe medications and perform necessary procedures to prevent harmful blood clots. […] Reactive thrombocytosis gets better when the underlying problem resolves. Although your platelet count is elevated for a short time (or even long-term after splenectomy), secondary thrombocytosis doesn’t typically lead to abnormal blood clotting.

• #2 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  In severe cases, thrombocytosis can cause dangerous clots in your blood vessels, increasing your risk of a stroke or heart attack. […] Your experience of thrombocytosis, including its seriousness and whether you need treatment, depends on its cause. […] High platelets aren’t life-threatening, but the complications that can result from the condition blood clots or severe bleeding can be. […] The most common causes of thrombocytosis are short-lived and don’t put you at risk of serious blood clots. The risk is greater with essential thrombocytosis. Still, your healthcare provider will monitor you closely, prescribe medications and perform necessary procedures to prevent harmful blood clots. […] Reactive thrombocytosis gets better when the underlying problem resolves. Although your platelet count is elevated for a short time (or even long-term after splenectomy), secondary thrombocytosis doesn’t typically lead to abnormal blood clotting.

• #3 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  In severe cases, thrombocytosis can cause dangerous clots in your blood vessels, increasing your risk of a stroke or heart attack. […] Your experience of thrombocytosis, including its seriousness and whether you need treatment, depends on its cause. […] High platelets aren’t life-threatening, but the complications that can result from the condition blood clots or severe bleeding can be. […] The most common causes of thrombocytosis are short-lived and don’t put you at risk of serious blood clots. The risk is greater with essential thrombocytosis. Still, your healthcare provider will monitor you closely, prescribe medications and perform necessary procedures to prevent harmful blood clots. […] Reactive thrombocytosis gets better when the underlying problem resolves. Although your platelet count is elevated for a short time (or even long-term after splenectomy), secondary thrombocytosis doesn’t typically lead to abnormal blood clotting.

• #4 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Essential thrombocythemia (ET), or primary thrombocytosis, can cause serious bleeding or clotting complications. Taking medicine that keeps your platelet levels normal can help prevent this. After many years of having the disease, however, bone marrow fibrosis (scarring) can develop. A small percentage of people with essential thrombocythemia develop leukemia.

• #5 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Essential thrombocythemia (ET), or primary thrombocytosis, can cause serious bleeding or clotting complications. Taking medicine that keeps your platelet levels normal can help prevent this. After many years of having the disease, however, bone marrow fibrosis (scarring) can develop. A small percentage of people with essential thrombocythemia develop leukemia.

• #6 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Essential thrombocythemia (ET), or primary thrombocytosis, can cause serious bleeding or clotting complications. Taking medicine that keeps your platelet levels normal can help prevent this. After many years of having the disease, however, bone marrow fibrosis (scarring) can develop. A small percentage of people with essential thrombocythemia develop leukemia.

• #7 Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5264-y

  Overall, 11 studies involving 3439 patients were contained in this study. The results revealed that pretreatment thrombocytosis was significantly related to a decreased OS (pooled HR=2.99; 95% CI=2.353.8; P0.001) and DFS (pooled HR=2.86; 95% CI=2.273.6; P 0.001) in patients with EC. […] Pretreatment thrombocytosis is an adverse prognostic marker in patients with EC. […] Our results demonstrated that pretreatment thrombocytosis predicts a worse OS and DFS in patients with EC. […] According to our findings, pretreatment thrombocytosis was significantly associated with advanced FIGO stage, tumor grade, LVSI, LN metastasis, recurrence, and VTE. […] In conclusion, this systematic review demonstrated that pretreatment thrombocytosis is correlated with poor survival outcome and adverse clinicopathological parameters in EC, and thrombocytosis is a potential prognosis predictor for EC.

• #8 Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6332560/

  Pretreatment thrombocytosis is an adverse prognostic marker in patients with EC. […] The results revealed that pretreatment thrombocytosis was significantly related to a decreased OS (pooled HR=2.99; 95% CI=2.353.8; P 0.001) and DFS (pooled HR=2.86; 95% CI=2.273.6; P 0.001) in patients with EC. […] Our results demonstrated that pretreatment thrombocytosis predicts a worse OS and DFS in patients with EC. […] According to our findings, pretreatment thrombocytosis was significantly associated with advanced FIGO stage, tumor grade, LVSI, LN metastasis, recurrence, and VTE. […] In conclusion, this systematic review demonstrated that pretreatment thrombocytosis is correlated with poor survival outcome and adverse clinicopathological parameters in EC, and thrombocytosis is a potential prognosis predictor for EC.

• #9 Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5264-y

  Overall, 11 studies involving 3439 patients were contained in this study. The results revealed that pretreatment thrombocytosis was significantly related to a decreased OS (pooled HR=2.99; 95% CI=2.353.8; P0.001) and DFS (pooled HR=2.86; 95% CI=2.273.6; P 0.001) in patients with EC. […] Pretreatment thrombocytosis is an adverse prognostic marker in patients with EC. […] Our results demonstrated that pretreatment thrombocytosis predicts a worse OS and DFS in patients with EC. […] According to our findings, pretreatment thrombocytosis was significantly associated with advanced FIGO stage, tumor grade, LVSI, LN metastasis, recurrence, and VTE. […] In conclusion, this systematic review demonstrated that pretreatment thrombocytosis is correlated with poor survival outcome and adverse clinicopathological parameters in EC, and thrombocytosis is a potential prognosis predictor for EC.

• #10 Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6332560/

  Pretreatment thrombocytosis is an adverse prognostic marker in patients with EC. […] The results revealed that pretreatment thrombocytosis was significantly related to a decreased OS (pooled HR=2.99; 95% CI=2.353.8; P 0.001) and DFS (pooled HR=2.86; 95% CI=2.273.6; P 0.001) in patients with EC. […] Our results demonstrated that pretreatment thrombocytosis predicts a worse OS and DFS in patients with EC. […] According to our findings, pretreatment thrombocytosis was significantly associated with advanced FIGO stage, tumor grade, LVSI, LN metastasis, recurrence, and VTE. […] In conclusion, this systematic review demonstrated that pretreatment thrombocytosis is correlated with poor survival outcome and adverse clinicopathological parameters in EC, and thrombocytosis is a potential prognosis predictor for EC.

• #11

  https://d-nb.info/1176829041/34

  Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis.

• #12 Thrombocytosis predicts poor prognosis of Asian patients with colorectal cancer: A systematic review and meta-analysis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9439792/

  Thrombocytosis was associated with a poorer overall survival (HR of 1.88 [95% CI: 1.24-2.85; P = .003] with univariate analyses, HR of 2.07 [95% CI: 1.23-3.56; P = .008] with multivariate analyses), disease-free survival (HR of 2.58 [95% CI: 1.87-3.57; P < .00001] with multivariate analyses) and cancer specific survival (HR of 2.55 [95% CI: 1.68-3.85; P < .00001]) in Asian patients with CRC. [...] The present meta-analysis demonstrates that thrombocytosis is a potentially useful tool for predicting poor survival in Asian patients with CRC, especially for overall survival. [...] Our meta-analysis of 13 independent studies with 3964 CRC cases unequivocally supported that thrombocytosis predicted a poorer survival of Asian CRC patients based on OS in both univariate and multivariate analyses and DFS and CSS in multivariate analysis. [...] This meta-analysis provided strong evidence to support claims that thrombocytosis was an independent prognostic factor in predicting survival of Asian CRC patients.

• #13 The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis | Oncotarget

  https://www.oncotarget.com/article/15358/text/

  Previous studies reported inconsistent findings about the relationship between pretreatment thrombocytosis and survival in patients with cervical cancer. This study aimed to evaluate the prognostic significance of thrombocytosis in cervical cancer. Overall, an elevated platelet count was significantly associated with inferior overall survival (OS, hazard ratio [HR]: 1.66, 95% confidence interval [CI]: 1.421.95, P 0.001) and recurrence-free survival (RFS, HR: 1.67, 95% CI: 1.152.42, P = 0.007) but not progression-free survival (PFS, HR: 1.21, 95% CI: 0.891.64; P = 0.235). […] Moreover, a pretreatment thrombocytosis status was significantly associated with higher clinical stage (odd ratio [OR]: 2.39, 95% CI: 1.683.38, P 0.001), positive pelvic node status (OR: 1.58, 95% CI: 1.01 2.45, P = 0.044) and larger tumor size (OR: 2.32, 95% CI: 1.393.87, P = 0.001). Pretreatment thrombocytosis is an independent prognosis predictor in cervical cancer patients. It may be used as a readily available biomarker to refine clinical outcome prediction for cervical cancer patients.

• #14 The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis | Oncotarget

  https://www.oncotarget.com/article/15358/text/

  In the present study, the results indicated that pretreatment thrombocytosis predicts poor oncologic outcome for patients with cervical cancer, which is accordance with a previous study. The results presented that patients with pretreatment thrombocytosis in cervical cancer are prone to suffer a poor OS and RFS. […] Our findings also identified that cervical cancer patients with pretreatment elevated platelet count are prone to suffer a higher clinical stage, positive pelvic node metastasis and a larger tumor size, which are indicative of poor prognosis and disease aggressiveness. So platelet count is a solid prognostic factor in cervical cancer. […] Despite the limitations described above, our comprehensive systematic review and meta-analysis reveals that pretreatment thrombocytosis is significantly associated with inferior OS and RFS in cervical cancer patients. It may be used as a readily available biomarker supplying conventional clinicopathological variables to refine clinical outcome prediction for cervical cancer patients, though large prospective studies are needed to demonstrate our findings.

• #15 A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients | Scientific Reports

  https://www.nature.com/articles/s41598-018-25019-1

  Platelets, components of hemostasis, when present in excess (400K/L, thrombocytosis) have also been associated with worse outcomes in lung, ovarian, breast, renal, and colorectal cancer patients. […] Our study indicates the association of temporally derived platelet count features with a patients prognosis predictions. […] Thrombocytosis, defined as a platelet count of 400K/L of blood, has been observed in cancer patients and it associates with poor prognosis in colorectal, breast, lung, renal, cervical, pancreatic, brain and ovarian cancers with a 15-40% occurrence. […] Our model incorporated many engineered features that would describe the behavior of the platelet counts within a given time period. […] It remains unknown whether the raised platelet counts are related to the cancer itself.

• #16 A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients | Scientific Reports

  https://www.nature.com/articles/s41598-018-25019-1

  Platelets, components of hemostasis, when present in excess (400K/L, thrombocytosis) have also been associated with worse outcomes in lung, ovarian, breast, renal, and colorectal cancer patients. […] Our study indicates the association of temporally derived platelet count features with a patients prognosis predictions. […] Thrombocytosis, defined as a platelet count of 400K/L of blood, has been observed in cancer patients and it associates with poor prognosis in colorectal, breast, lung, renal, cervical, pancreatic, brain and ovarian cancers with a 15-40% occurrence. […] Our model incorporated many engineered features that would describe the behavior of the platelet counts within a given time period. […] It remains unknown whether the raised platelet counts are related to the cancer itself.

• #17 A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients | Scientific Reports

  https://www.nature.com/articles/s41598-018-25019-1

  What is important is that the presence of elevated platelet counts is associated with a worse prognosis. […] Our analysis showed that abnormal platelet counts up to a year prior to the diagnosis of cancer was better able to delineate patients with similar stage cancers and probability for five-year survival. […] Overall, we delineated temporal platelet count variability and found that predictions leveraging temporal platelet count information, as opposed to just measuring platelet counts around the time of treatment, can improve prognosis predictions in a stage and type of cancer-dependent manner.

• #18 Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism | Blood Cancer Journal

  https://www.nature.com/articles/s41408-021-00585-2

  Patients with thrombocytosis experienced significantly better overall survival in comparison to both patients with normal platelet count (hazard ratio HR 0.75; P=0.016) and thrombocytopenia (HR 0.47; P=0.001) with in-hospital mortality rates of 24.1%, 31.5%, and 45.6%, respectively. […] Gradually improving overall survival could be observed in patients with higher platelets, even with further subdivision of patients with low, normal, and elevated platelet count as shown in Fig. 1B (P=0.001 for difference and P=0.001 for trend; platelets stratified to 50, 50-99, 100-149, 150-299, 300-449, 450-599 and 600-109/L). […] Higher platelets were also associated with a lower rate of bacterial sepsis highlighting their important role in the immune system. It is of special interest that the frequency of VTE was significantly higher among COVID-19 patients with higher platelet count.

• #19 Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism | Blood Cancer Journal

  https://www.nature.com/articles/s41408-021-00585-2

  Patients with thrombocytosis experienced significantly better overall survival in comparison to both patients with normal platelet count (hazard ratio HR 0.75; P=0.016) and thrombocytopenia (HR 0.47; P=0.001) with in-hospital mortality rates of 24.1%, 31.5%, and 45.6%, respectively. […] Gradually improving overall survival could be observed in patients with higher platelets, even with further subdivision of patients with low, normal, and elevated platelet count as shown in Fig. 1B (P=0.001 for difference and P=0.001 for trend; platelets stratified to 50, 50-99, 100-149, 150-299, 300-449, 450-599 and 600-109/L). […] Higher platelets were also associated with a lower rate of bacterial sepsis highlighting their important role in the immune system. It is of special interest that the frequency of VTE was significantly higher among COVID-19 patients with higher platelet count.

• #20 Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism | Blood Cancer Journal

  https://www.nature.com/articles/s41408-021-00585-2

  These findings highly resemble phenomena reported in MPN patients with COVID-19 where patients with essential thrombocythemia (ET) who presented with higher platelet count in comparison to other MPN subsets were reported to have a higher risk for VTE but favorable disease course. […] Hence, our data suggest that these observations might not be MPN-specific and could represent biological phenomena present in patients with non-clonally elevated platelet count as well.

• #21

  https://haematologica.org/article/view/7718

  Pregnant woman with essential thrombocythemia (ET) are at higher than normal risk of pregnancy complications. […] From our case series, including 10 pregnancies, we demonstrate that PEG-IFN has been well-tolerated, allows reduction and control of platelet count during pregnancy, and is associated with a high live birth rate (90%) and low miscarriage rate (10%). […] Previous descriptive studies of pregnancy in women with ET suggested a risk of first trimester miscarriage of 27% with a live birth rate of only 64%. […] The study included 10 pregnancies in 8 women observed between 2013 and 2015. […] Of the 10 pregnancies, all were singleton. Nine (90%) resulted in live birth and one (10%) in miscarriage (at 7 weeks, platelet count 49210/L). […] Finally, when comparing outcomes of pregnancies of these 8 women on PEG-IFN or without (after having excluded 1 voluntary termination of pregnancy from the analysis), there were significantly more live births on PEG-IFN (9 vs. 3; P<0.05) and fewer miscarriages (1 vs. 5; P<0.05).

• #22

  https://haematologica.org/article/view/7718

  Pregnant woman with essential thrombocythemia (ET) are at higher than normal risk of pregnancy complications. […] From our case series, including 10 pregnancies, we demonstrate that PEG-IFN has been well-tolerated, allows reduction and control of platelet count during pregnancy, and is associated with a high live birth rate (90%) and low miscarriage rate (10%). […] Previous descriptive studies of pregnancy in women with ET suggested a risk of first trimester miscarriage of 27% with a live birth rate of only 64%. […] The study included 10 pregnancies in 8 women observed between 2013 and 2015. […] Of the 10 pregnancies, all were singleton. Nine (90%) resulted in live birth and one (10%) in miscarriage (at 7 weeks, platelet count 49210/L). […] Finally, when comparing outcomes of pregnancies of these 8 women on PEG-IFN or without (after having excluded 1 voluntary termination of pregnancy from the analysis), there were significantly more live births on PEG-IFN (9 vs. 3; P<0.05) and fewer miscarriages (1 vs. 5; P<0.05).

• #23

  https://haematologica.org/article/view/7718

  This observational study (including 10 pregnancies in 8 ET patients) is the first case series of pregnant women treated with PEG-IFN evaluating pregnancy outcome, tolerance and safety. […] In terms of hematologic efficacy, platelet counts were well controlled with PEG-IFN, during pregnancy. […] Current guidelines recommend using IFN as first-line for high-risk pregnant patients. […] Our results highlight efficacy, safety and good tolerance of PEG-IFN, which could be an effective and safe alternative to IFN for pregnant woman with ET requiring cytoreduction.

• #24 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  In severe cases, thrombocytosis can cause dangerous clots in your blood vessels, increasing your risk of a stroke or heart attack. […] Your experience of thrombocytosis, including its seriousness and whether you need treatment, depends on its cause. […] High platelets aren’t life-threatening, but the complications that can result from the condition blood clots or severe bleeding can be. […] The most common causes of thrombocytosis are short-lived and don’t put you at risk of serious blood clots. The risk is greater with essential thrombocytosis. Still, your healthcare provider will monitor you closely, prescribe medications and perform necessary procedures to prevent harmful blood clots. […] Reactive thrombocytosis gets better when the underlying problem resolves. Although your platelet count is elevated for a short time (or even long-term after splenectomy), secondary thrombocytosis doesn’t typically lead to abnormal blood clotting.

• #25 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  In severe cases, thrombocytosis can cause dangerous clots in your blood vessels, increasing your risk of a stroke or heart attack. […] Your experience of thrombocytosis, including its seriousness and whether you need treatment, depends on its cause. […] High platelets aren’t life-threatening, but the complications that can result from the condition blood clots or severe bleeding can be. […] The most common causes of thrombocytosis are short-lived and don’t put you at risk of serious blood clots. The risk is greater with essential thrombocytosis. Still, your healthcare provider will monitor you closely, prescribe medications and perform necessary procedures to prevent harmful blood clots. […] Reactive thrombocytosis gets better when the underlying problem resolves. Although your platelet count is elevated for a short time (or even long-term after splenectomy), secondary thrombocytosis doesn’t typically lead to abnormal blood clotting.

• #26

  https://haematologica.org/article/view/7718

  This observational study (including 10 pregnancies in 8 ET patients) is the first case series of pregnant women treated with PEG-IFN evaluating pregnancy outcome, tolerance and safety. […] In terms of hematologic efficacy, platelet counts were well controlled with PEG-IFN, during pregnancy. […] Current guidelines recommend using IFN as first-line for high-risk pregnant patients. […] Our results highlight efficacy, safety and good tolerance of PEG-IFN, which could be an effective and safe alternative to IFN for pregnant woman with ET requiring cytoreduction.

• #27 The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis | Oncotarget

  https://www.oncotarget.com/article/15358/text/

  In the present study, the results indicated that pretreatment thrombocytosis predicts poor oncologic outcome for patients with cervical cancer, which is accordance with a previous study. The results presented that patients with pretreatment thrombocytosis in cervical cancer are prone to suffer a poor OS and RFS. […] Our findings also identified that cervical cancer patients with pretreatment elevated platelet count are prone to suffer a higher clinical stage, positive pelvic node metastasis and a larger tumor size, which are indicative of poor prognosis and disease aggressiveness. So platelet count is a solid prognostic factor in cervical cancer. […] Despite the limitations described above, our comprehensive systematic review and meta-analysis reveals that pretreatment thrombocytosis is significantly associated with inferior OS and RFS in cervical cancer patients. It may be used as a readily available biomarker supplying conventional clinicopathological variables to refine clinical outcome prediction for cervical cancer patients, though large prospective studies are needed to demonstrate our findings.

• #28 A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients | Scientific Reports

  https://www.nature.com/articles/s41598-018-25019-1

  What is important is that the presence of elevated platelet counts is associated with a worse prognosis. […] Our analysis showed that abnormal platelet counts up to a year prior to the diagnosis of cancer was better able to delineate patients with similar stage cancers and probability for five-year survival. […] Overall, we delineated temporal platelet count variability and found that predictions leveraging temporal platelet count information, as opposed to just measuring platelet counts around the time of treatment, can improve prognosis predictions in a stage and type of cancer-dependent manner.

• #29 Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism | Blood Cancer Journal

  https://www.nature.com/articles/s41408-021-00585-2

  Patients with thrombocytosis experienced significantly better overall survival in comparison to both patients with normal platelet count (hazard ratio HR 0.75; P=0.016) and thrombocytopenia (HR 0.47; P=0.001) with in-hospital mortality rates of 24.1%, 31.5%, and 45.6%, respectively. […] Gradually improving overall survival could be observed in patients with higher platelets, even with further subdivision of patients with low, normal, and elevated platelet count as shown in Fig. 1B (P=0.001 for difference and P=0.001 for trend; platelets stratified to 50, 50-99, 100-149, 150-299, 300-449, 450-599 and 600-109/L). […] Higher platelets were also associated with a lower rate of bacterial sepsis highlighting their important role in the immune system. It is of special interest that the frequency of VTE was significantly higher among COVID-19 patients with higher platelet count.

Zobacz więcej